Chugai Pharmaceutical Opens a North American Hub in New Jersey
On Nov. 20, 2015, Chugai Pharma USA Inc. (CPUSA), a subsidiary of Chugai Pharmaceutical Co, Ltd. (Chugai), announced the opening of its new office, dedicated to translational clinical research, in Berkeley Heights, NJ. The new facility serves as the North American hub for Chugai, a research-based pharmaceutical company headquartered in Tokyo, according to a press release.
CPUSA is focused on early development and, in spring of 2015, established Chugai's Translational Clinical Research Division (TCRD). TCRD is Chugai's first global organization composed of functions in Japan, Europe, and the United States.
Chugai focuses on advancing treatment in oncology, bone and joint diseases, renal diseases, and autoimmune diseases. The company also maintains an alliance with Roche, leveraging its resources to pursue biopharmaceutical, antibody, and molecular-targeted research technologies as well as chemical synthesis technology.
CPUSA currently has the following three ongoing development programs:
- SA237, anti-IL-6 receptor humanized monoclonal antibody applied with recycling antibody technology (Chugai's proprietary antibody engineering technology) for neuromyelitis optica (Phase III)
- CIM331, anti-IL-31 receptor humanized monoclonal antibody for atopic dermatitis (Phase II)
- PCO371, PTH1 receptor agonist for hypoparathyroidism (Phase I).
Source: Chugai Pharmaceuticals
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
